ECSP003652A - TREATMENT OF COMBINATION WITH I1-1ra AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1 - Google Patents

TREATMENT OF COMBINATION WITH I1-1ra AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1

Info

Publication number
ECSP003652A
ECSP003652A EC2000003652A ECSP003652A ECSP003652A EC SP003652 A ECSP003652 A EC SP003652A EC 2000003652 A EC2000003652 A EC 2000003652A EC SP003652 A ECSP003652 A EC SP003652A EC SP003652 A ECSP003652 A EC SP003652A
Authority
EC
Ecuador
Prior art keywords
release
combination
processing
inhibit
compounds
Prior art date
Application number
EC2000003652A
Other languages
Spanish (es)
Inventor
Joseph Tardio
Paul Hadvary
Hans Lengsfeld
Hans Steffen
Bruce Henry Littman
Marcel Schmid
Farland Small Donald Mac
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP003652A publication Critical patent/ECSP003652A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El invento se refiere a métodos y composiciones para tratar y prevenir estados de enfermedad por la interleuquina 1 (IL-1). En los métodos y las composiciones se usa un polipáptido antagonista del receptor de la interleuquina 1(I1-1ra.), o una variante del mismo, en combinación con un agente no esteroide que inhibe el procesamiento y la liberación del I1-1.The invention relates to methods and compositions for treating and preventing disease states by interleukin 1 (IL-1). In methods and compositions, an interleukin 1 receptor antagonist polypeptide (I1-1ra.), Or a variant thereof, is used in combination with a non-steroid agent that inhibits the processing and release of I1-1.

EC2000003652A 1999-09-14 2000-09-12 TREATMENT OF COMBINATION WITH I1-1ra AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1 ECSP003652A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
ECSP003652A true ECSP003652A (en) 2002-04-23

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003652A ECSP003652A (en) 1999-09-14 2000-09-12 TREATMENT OF COMBINATION WITH I1-1ra AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1

Country Status (13)

Country Link
EP (1) EP1214087A1 (en)
JP (1) JP2003509378A (en)
AR (1) AR033650A1 (en)
AU (1) AU6464400A (en)
BR (1) BR0014003A (en)
CA (1) CA2383026A1 (en)
CO (1) CO5190701A1 (en)
EC (1) ECSP003652A (en)
GT (1) GT200000155A (en)
PA (1) PA8502901A1 (en)
PE (1) PE20010685A1 (en)
TN (1) TNSN00183A1 (en)
WO (1) WO2001019390A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005231822B2 (en) 2004-04-02 2011-07-21 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
WO2008129288A2 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
PE20180160A1 (en) 2015-02-16 2018-01-18 Univ Queensland SULFONYLUREAS AND RELATED COMPOUNDS AND THE USE OF THEM
CN109071454B (en) 2016-02-16 2023-02-17 昆士兰大学 Sulfonylureas and related compounds and uses thereof
ES2927777T3 (en) 2016-04-18 2022-11-10 Novartis Ag Compounds and compositions for the treatment of conditions associated with NLRP activity
BR112019014549A2 (en) 2017-01-23 2020-02-18 Genentech, Inc. COMPOUNDS OF FORMULAS I, IG, IH, IE, COMPOUNDS, PHARMACEUTICAL COMPOSITION, TREATMENT METHODS, MODULATION OF THE ACTIVITY OF A BIOLOGICAL TARGET, INHIBITION OF THE INFLAMASSOMA ACTIVATION AND USE OF A COMPOUND
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
LT3661925T (en) 2017-07-07 2022-03-10 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CN111094243B (en) 2017-07-24 2023-09-05 诺华股份有限公司 Compounds and compositions for treating disorders associated with NLRP activity
WO2019034690A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
MA49904A (en) 2017-08-15 2020-06-24 Inflazome Ltd NEW SULFONAMIDE CARBOXAMIDE COMPOUNDS
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
TW201910317A (en) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 Novel compound
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited Novel substituted sulfonylurea derivatives
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited Novel compounds
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
JP2021529187A (en) 2018-07-03 2021-10-28 ノバルティス アーゲー NLRP modulator
BR112021001012A2 (en) 2018-07-20 2021-04-20 F. Hoffmann-La Roche Ag sulfonylurea compounds as inhibitors of interleukin-1 activity
WO2020086732A1 (en) 2018-10-24 2020-04-30 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
EA202191968A1 (en) 2019-01-14 2021-11-16 Кадила Хелзкэр Лимитед NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
JP2023527816A (en) * 2020-05-25 2023-06-30 ベイジン ブイディージェイバイオ カンパニー， リミテッド Interleukin-1 receptor antagonists and fusion proteins containing the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
JP3573757B2 (en) * 1997-01-29 2004-10-06 ファイザー・インク Sulfonylurea derivatives and use of the sulfonylurea derivatives in controlling interleukin-1 activity
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins

Also Published As

Publication number Publication date
AR033650A1 (en) 2004-01-07
CA2383026A1 (en) 2001-03-22
CO5190701A1 (en) 2002-08-29
JP2003509378A (en) 2003-03-11
PE20010685A1 (en) 2001-07-03
TNSN00183A1 (en) 2005-11-10
EP1214087A1 (en) 2002-06-19
AU6464400A (en) 2001-04-17
WO2001019390A1 (en) 2001-03-22
GT200000155A (en) 2002-03-08
PA8502901A1 (en) 2002-02-21
BR0014003A (en) 2002-05-21

Similar Documents

Publication Publication Date Title
ECSP003652A (en) TREATMENT OF COMBINATION WITH I1-1ra AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1
UY26296A1 (en) DRUG TREATMENT OF INQUIET LEGS SYNDROME
ES2146300T3 (en) USE OF ANTIHELMINTIC COMPOSITIONS FOR THE TREATMENT OF INFECTIONS CAUSED BY ANOPLOCEPHALA PERFOLIATA IN EQUIDS.
MX9203444A (en) MEDICINES.
ES2188177T3 (en) COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF OSTEOPOROSIS AND ALTERATIONS DUE TO MENOPAUSE SYNDROME, WHICH INCLUDES PROPIONIL-L-CARNITINE AND GENISTEINE.
AR012671A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF THE CONSTIPATION, THE USES OF SUCH COMPOSITIONS AND THE PROCESSES TO PREPARE THEM
UY26391A1 (en) SGLT2 INHIBITORS OF C-ARYL GLUCOSIDES AND METHOD
CR9842A (en) CELECOXIB COMPOSITIONS
CO5160320A1 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION OF TOLERANCE TO MEDICINES DAS.
CL2009001279A1 (en) Nociceptin derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of pain (sol. divisional 2103-03).
PA8484301A1 (en) PHARMACEUTICAL FORMULATIONS OF CONTROLLED LIBERATION
AR031473A1 (en) GABA INTENSIFIERS IN THE TREATMENT OF DISEASES RELATED TO A REDUCED NEUROSTEROID ACTIVITY
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
ES2196190T3 (en) INHIBITORS OF METALOPROTEINASAS MATRICIALES, WITH BIFENLICO HYDROXAMATE.
CY1114133T1 (en) Substituted c-phenyl-D-lactams and their related uses
BR0107628A (en) 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation
PE20010642A1 (en) PRAMIPEXOL AND CLONIDINE COMBINATION FOR THE TREATMENT OF RESTLESS LEGS SYNDROME
ECSP003807A (en) VALDECOXIB COMPOSITIONS
CO5570661A2 (en) COMBINATIONS THAT INCLUDE COX-2 AND ASPIRINE INHIBITORS
AR043660A1 (en) THE TREATMENT OF ALZHEIMER'S DISEASE
AR021690A1 (en) USE OF KTQ1 CHANNEL INHIBITORS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES, WHICH ARE CAUSED BY YECTOPARASITES HELMENTS.
CL2004001421A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM 1,4-DIPIPERIDIN-4-IL-PIPERAZINA; AND ITS USE FOR THE PREVENTION AND / OR TREATMENT OF PAIN.
AR032422A1 (en) USE OF IL-18 INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF CARDIAC DISEASE
AR028502A1 (en) TREATMENT OF ALLERGIC INFLAMMATORY CONDITIONS
AR022250A1 (en) PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B.